Impetigo is a common superficial bacterial infection of the skin, typically treated with topical antibiotics. The bacteria involved in causing impetigo are S. aureus and S. pyogenes. Mupirocin, often under the brand name Bactroban, is commonly used to treat impetigo.
Xepi, a new topical antibiotic for treating impetigo has recently been approved. Xepi is a topical non-fluorinated quinolone that is applied twice daily for five days. In clinical studies, Xepi was shown to be effective, safe, and well tolerated, with negligible systemic absorption.
The introduction of Xepi increases the number of choices available to dermatologists in the treatment of impetigo.